KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Intangibles (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Change in Intangibles data on record, last reported at -$7.7 million in Q4 2025.

  • For Q4 2025, Change in Intangibles rose 22.62% year-over-year to -$7.7 million; the TTM value through Sep 2025 reached -$2.3 million, up 97.2%, while the annual FY2023 figure was $11.2 million, 687.6% up from the prior year.
  • Change in Intangibles reached -$7.7 million in Q4 2025 per SRPT's latest filing, down from $5.3 million in the prior quarter.
  • Across five years, Change in Intangibles topped out at $101.9 million in Q3 2023 and bottomed at -$99.7 million in Q4 2021.
  • Average Change in Intangibles over 5 years is -$6.7 million, with a median of $188000.0 recorded in 2025.
  • Peak YoY movement for Change in Intangibles: plummeted 45031.19% in 2023, then surged 10538.3% in 2024.
  • A 5-year view of Change in Intangibles shows it stood at -$99.7 million in 2021, then soared by 100.2% to $202000.0 in 2022, then tumbled by 45031.19% to -$90.8 million in 2023, then skyrocketed by 88.98% to -$10.0 million in 2024, then rose by 22.62% to -$7.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Intangibles were -$7.7 million in Q4 2025, $5.3 million in Q3 2025, and $188000.0 in Q2 2025.